Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà¹ÞÀº ÄÚÀÎµÎ¾Ï È¯ÀÚ¿¡¼­ÀÇ ±¸°­°ÇÁ¶Áõ ºÐ¼® Evaluation of Xerostomia Following 3 Dimensional Conformal Radiotherapy for Nasopharyngeal Cancer Patients

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2006³â 24±Ç 2È£ p.81 ~ 87
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¿µÁ¦/Park YJ ¾È¿ëÂù/¹Ú ¿ø/ÁÖ»ó±Ô/³²Èñ¸²/¿Àµ¿·Ä/¹ÚÈñö/Ahn YC/Park W/Ju SG/Nam HR/Oh DR/Park HC

Abstract

¸ñ Àû: 3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà ¹ÞÀº ÄÚÀÎµÎ¾Ï È¯ÀÚ¿¡¼­ ¼³¹®Á¶»ç¸¦ ÀÌ¿ëÇÏ¿© ±¸°­°ÇÁ¶ÁõÀÇ ½Ã°£°æ°ú¿¡ µû¸¥ º¯È­¾ç»óÀ» ºÐ¼®ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 2000³â 12¿ùºÎÅÍ 2005³â 8¿ù±îÁö ÄÚÀÎµÎ¾Ï È¯ÀÚ¿¡¼­ 3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼±Ä¡·á¸¦ Àû¿ëÇÑ È¯ÀÚ 51¸íÀ» ¼³¹®Á¶»çÀÇ ´ë»óÀ¸·Î ÇÏ¿´´Ù. 3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼±Ä¡·á´Â 3ȸÀÇ ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(Computed tomography:CT)¸ðÀÇÄ¡·á¸¦ ÀÌ¿ëÇÑ 3´Ü°è Ä¡·á°èȹÀ» ½ÃÇàÇÏ´Â ¼øÂ÷Àû Á¶»ç¿µ¿ª Ãà¼Ò¹æ¹ýÀ» »ç¿ëÇÏ¿´°í, ÃÑ ¼±·® 72 Gy¸¦ ¸ñÇ¥·Î ÇÏ¿´´Ù. ±¸°­°ÇÁ¶ÁõÀº ÀÏ»ó»ýÈ°¿¡¼­ Áß¿äÇÑ 4°¡Áö Ç׸ñÀ¸·Î ±¸¼ºµÈ ¼³¹®Á¡¼ö(xerostomia questionnaire score: XQS)¸¦ ÃøÁ¤ÇÏ¿´À¸¸ç, ¹æ»ç¼±Ä¡·á ÈÄ °æ°ú½Ã°£, ¼ºº°, ³ªÀÌ, º´±â, Ç×¾ÏÄ¡·áÀÇ º´¿ëÀ¯¹«, ±×¸®°í ÀÌÇϼ±ÀÇ Æò±Õ ¹æ»ç¼±·® µî¿¡ µû¸£´Â Â÷À̸¦ ºÐ¼®ÇÏ¿´´Ù.

°á °ú: Ç×¾ÏÄ¡·á¸¦ º´¿ëÇÑ È¯ÀÚ°¡ 40¸í, ¹æ»ç¼±Ä¡·á ´Üµ¶È¯ÀÚ°¡ 11¸íÀ̾úÀ¸¸ç, ¹æ»ç¼±Ä¡·á ÈÄ ¼³¹®Á¶»ç±îÁö °æ°ú ½Ã°£Àº Áß¾Ó°ª 20 (1¡­58)°³¿ùÀ̾ú´Ù. Àüü ȯÀÚ¿¡¼­ XQS Á¡¼öÀÇ Æò±ÕÀº 8.4Á¡(ÃÖÇÏ 6Á¡, ÃÖ°í 14Á¡, Ç¥ÁØÆíÂ÷ 1.9) À̾ú´Ù. ¹æ»ç¼±Ä¡·á ÈÄ °æ°ú½Ã°£¿¡ µû¶ó XQS Á¡¼ö´Â Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô °¨¼ÒÇÏ´Â °æÇâÀ» º¸¿´´Ù(¥ö2=-0.484, p£¼ 0.05). ¼ºº°, ³ªÀÌ, º´±â¿¡ µû¶ó XQS Á¡¼öÀÇ Â÷ÀÌ´Â ¾ø¾ú°í, Ç×¾ÏÄ¡·á¸¦ º´¿ëÇÑ È¯ÀÚ¿¡¼­ ¹æ»ç¼±Ä¡·á ´Üµ¶ ȯÀÚ¿Í ºñ±³ÇÏ¿© XQS Á¡¼ö°¡ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù(p=0.001). Àüü ÀÌÇϼ±ÀÇ Æò±Õ¼±·®Àº 35 Gy ¹Ì¸¸¿¡¼­ 35 Gy À̻󺸴٠XQS Á¡¼ö°¡ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô ³·¾Ò´Ù(p=0.05).

°á ·Ð: ÄÚÀÎµÎ¾Ï È¯ÀÚ¿¡¼­ 3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼±Ä¡·á ÈÄ ÃøÁ¤ÇÑ XQS Á¡¼ö´Â ¹æ»ç¼±Ä¡·á ÈÄ ½Ã°£°æ°ú¿¡ µû¶ó °¨¼ÒÇÏ´Â ¾ç»óÀ» º¸¿´À¸¸ç, Ç×¾ÏÄ¡·á¸¦ º´¿ëÇÔÀ¸·Î½á ´õ ¾ÇÈ­µÇ´Â °æÇâÀÌ ÀÖ°í, ÀÌÇϼ±¿¡ Á¶»çµÇ´Â Æò±Õ¼±·®À» 35 Gy ¹Ì¸¸À¸·Î ÇÏ´Â °ÍÀÌ ±¸°­°ÇÁ¶Áõ Áõ»ó¿ÏÈ­¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ°Ú´Ù.

Purpose: This study is to evaluate the xerostomia following 3-dimensional conformal radiation therapy (3D CRT) in nasopharynx cancer patients using the xerostomia questionnaire score (XQS).

Materials and Methods: Questionnaire study was done on 51 patients with nasopharynx cancer who received 3D CRT from Dec. 2000 to Aug. 2005. 3D CRT technique is based on ¡°serial shrinking field¡± concept by 3 times of computed tomography (CT) simulation. Total target dose to the primary tumor was 72 Gy with 1.8 Gy daily fractions. Xerostomia was assessed with 4-questions XQS, and the associations between XQS and time elapsed after RT, age, sex, stage, concurrent chemotherapy, and parotid dose were analyzed.

Results: Concurrent chemotherapy was given to 40 patients and RT alone was given to 11 patients. The median time elapsed after 3D CRT was 20 (1¡­58) months and the mean XQS of all 51 patients was 8.4¡¾1.9 (6¡­14). XQS continuously and significantly decreased over time after 3D CRT (¥ö2=-0.484, p£¼0.05). There was no significant difference in XQS according to sex, age, and stag. However, XQS of concurrent chemotherapy patients was significantly higher than RT alone patients (p=0.001). XQS of patients receiving total mean parotid dose ¡Ã35 Gy was significantly higher than £¼35 Gy (p=0.05).

Conclusion: Decreasing tendency of XQS over time after 3D CRT was observed. Concurrent chemotherapy and total mean parotid dose ¡Ã35 Gy were suggested to adversely affect radiation-induced xerostomia.

Å°¿öµå

±¸°­°ÇÁ¶Áõ;ÄÚÀεξÏ;3Â÷¿ø ÀÔüÁ¶Çü ¹æ»ç¼±Ä¡·á;Xerostomia;Nasopharynx cancer;3 dimensional conformal radiation therapy

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS